Nodify XL2 Classifier Clinical Utility Study in Low to Moderate Risk Lung Nodules

NCT04171492 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2025-09-19

No results posted yet for this study

Summary

This study evaluates the how addition of the Nodify XL2 test result impacts the clinical management of newly identified solid lung nodules assessed as low to moderate risk of cancer.

Conditions

  • Nodule Solitary Pulmonary
  • Non-small Cell Carcinoma

Sponsors & Collaborators

  • Biodesix, Inc.

    lead INDUSTRY

Principal Investigators

  • Steven Springmeyer · Biodesix, Inc.

  • Gerard Silvestri, MD · Medical University of South Carolina

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-18
Primary Completion
2025-12-31
Completion
2026-12-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04171492 on ClinicalTrials.gov